- Home
- STI vs CTSO Comparison
STI vs CTSO Comparison
Compare STI & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- CTSO
- Stock Information
- Founded
- STI 2014
- CTSO 1997
- Country
- STI United States
- CTSO United States
- Employees
- STI N/A
- CTSO N/A
- Industry
- STI
- CTSO Medical/Dental Instruments
- Sector
- STI
- CTSO Health Care
- Exchange
- STI NYSE
- CTSO Nasdaq
- Market Cap
- STI 51.2M
- CTSO 61.3M
- IPO Year
- STI N/A
- CTSO N/A
- Fundamental
- Price
- STI $0.09
- CTSO $1.03
- Analyst Decision
- STI
- CTSO Strong Buy
- Analyst Count
- STI 0
- CTSO 3
- Target Price
- STI N/A
- CTSO $4.67
- AVG Volume (30 Days)
- STI 3.8M
- CTSO 74.6K
- Earning Date
- STI 06-06-2025
- CTSO 05-08-2025
- Dividend Yield
- STI N/A
- CTSO N/A
- EPS Growth
- STI N/A
- CTSO N/A
- EPS
- STI N/A
- CTSO N/A
- Revenue
- STI N/A
- CTSO $35,594,520.00
- Revenue This Year
- STI N/A
- CTSO $18.72
- Revenue Next Year
- STI N/A
- CTSO $19.75
- P/E Ratio
- STI N/A
- CTSO N/A
- Revenue Growth
- STI 32.73
- CTSO 14.51
- 52 Week Low
- STI $0.08
- CTSO $0.70
- 52 Week High
- STI $3.25
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- STI 36.91
- CTSO 53.19
- Support Level
- STI $0.08
- CTSO $0.93
- Resistance Level
- STI $0.17
- CTSO $1.07
- Average True Range (ATR)
- STI 0.02
- CTSO 0.06
- MACD
- STI 0.01
- CTSO 0.01
- Stochastic Oscillator
- STI 20.65
- CTSO 71.43
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.